These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 8751578)
1. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578 [TBL] [Abstract][Full Text] [Related]
2. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Moul JW Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496 [TBL] [Abstract][Full Text] [Related]
4. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. Borre M; Stausbol-Gron B; Overgaard J J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132 [TBL] [Abstract][Full Text] [Related]
5. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308 [TBL] [Abstract][Full Text] [Related]
6. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681 [TBL] [Abstract][Full Text] [Related]
9. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Keshgegian AA; Johnston E; Cnaan A Am J Clin Pathol; 1998 Oct; 110(4):443-9. PubMed ID: 9763029 [TBL] [Abstract][Full Text] [Related]
10. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339 [TBL] [Abstract][Full Text] [Related]
11. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158 [TBL] [Abstract][Full Text] [Related]
12. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947 [TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889 [TBL] [Abstract][Full Text] [Related]
15. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Stapleton AM; Zbell P; Kattan MW; Yang G; Wheeler TM; Scardino PT; Thompson TC Cancer; 1998 Jan; 82(1):168-75. PubMed ID: 9428494 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Rubio J; Ramos D; López-Guerrero JA; Iborra I; Collado A; Solsona E; Almenar S; Llombart-Bosch A Eur Urol; 2005 Nov; 48(5):745-51. PubMed ID: 16139948 [TBL] [Abstract][Full Text] [Related]
18. Prognostic markers in clinically localised prostate cancer. Bai XZ; Masters JR; O'Donoghue N; Kirby R; Pan LX; Young M; Stafford M; Parkinson MC Int J Oncol; 1999 Apr; 14(4):785-91. PubMed ID: 10087330 [TBL] [Abstract][Full Text] [Related]
19. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study. Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854 [TBL] [Abstract][Full Text] [Related]
20. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. Stackhouse GB; Sesterhenn IA; Bauer JJ; Mostofi FK; Connelly RR; Srivastava SK; Moul JW J Urol; 1999 Dec; 162(6):2040-5. PubMed ID: 10569564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]